

**Date and Time:** 28<sup>th</sup> February 2012, 10:30-16:30

**Minutes:** Confirmed

**Hepatitis B GDG Meeting 5**

**Place:** NCGC Boardroom, 180 Great Portland Street, London, W1W 5QZ

**Present:** GDG

|                          |     |
|--------------------------|-----|
| 1. Howard Thomas (Chair) | HT  |
| 2. Elizabeth Boxall      | EB  |
| 3. Javier Vilar          | JV  |
| 4. Angela Narbey         | AN  |
| 5. Geoffrey Dusheiko     | GD  |
| 6. Aftab Ala             | AA  |
| 7. Alan Mitchell         | AM  |
| 8. Gareth Tudor-Williams | GTW |
| 9. Emily Lam             | EL  |
| 10. Joyeta Das           | JD  |

NCGC Technical team

|                      |    |
|----------------------|----|
| 11. Gill Ritchie     | GR |
| 12. Grammati Sarri   | GS |
| 13. Rosa Lau         | RL |
| 14. Sarah Bermingham | SB |
| 15. Amy Kelsey       | AK |

NICE

|                   |    |
|-------------------|----|
| 16. Sarah Dunsdon | SD |
|-------------------|----|

Apologies

|                          |     |
|--------------------------|-----|
| 17. Grant Hill-Cawthorne | GHC |
|--------------------------|-----|

## Notes

1. The Chair welcomed the group to the Hepatitis B Guideline Development Group (GDG) meeting 5. Apologies were received from Grant Hill-Cawthorne. The Chair welcomed Joyeta Das, who attended the meeting as a co-opted Pharmacist.
2. The Chair asked the GDG to declare if they had any personal specific, personal non-specific, non-personal specific or non-personal non-specific interests to declare since their previous declaration (upon acceptance of their GDG role). No one declared any new conflicts of interest.
3. The Chair then briefed the group on the meetings objectives.
4. The Chair introduced Sarah Dunsdon, NICE Guidelines Commissioning manager, who gave a brief verbal update to the GDG on the changes to the quality standards process. The Chair thanked SD for her update.
5. The Chair introduced Grammati Sarri, NCGC Senior Research Fellow and Rosa Lau, NCGC Research Fellow, who gave a presentation on how frequently monitoring tests should be carried out to ascertain virological, serological and biochemical response and resolution of fibrosis in people with CHB. The Chair thanked GS and RL for their presentation.
6. The GDG then discussed the evidence presented and drafted recommendations.
7. GS then gave a presentation to the GDG on the Network Meta Analysis. The GDG then discussed the NMA and agreed on the protocol. The Chair thanked GS for her presentation.
8. GS and RL then led discussion with the GDG on the research protocol for 2 clinical questions. The protocols for referral thresholds and healthcare setting were agreed and signed off by the GDG.
9. There was no other business to discuss. The Chair closed the meeting and thanked everyone for attending.

## Date, time and venue of the next meeting

10. Tuesday 3<sup>rd</sup> April 2012, 10:30-16:30, NCGC Boardroom, 180 Great Portland Street, London, W1W 5QZ.